Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Patel Retail IPO Review, Analysis, Good or Bad

By Jagat Joshi
August 14, 2025

The Patel Retail IPO will open for subscription on August 19, 2025, and will be closed for subscription on August 21, 2025. Patel Retail IPO price band is set between ₹237 to ₹255 per share with a face value of ₹10 each. The firm has submitted its draft papers in order to raise funds of around ₹242.76 crores through an Initial Public Offering (IPO).

As an investor, deciding whether the IPO is Good or Bad to invest in can often be challenging. If you are confused and worried about whether to Apply or Not for the Patel Retail IPO. Then worry not, here we are describing 10 important key points & an in-depth, detailed Patel Retail IPO review and Analysis which will help you to make the decision.

Strengths and Weaknesses of Patel Retail IPO

Strengths:

Over the years, the company has shown Steady growth through a unique store acquisition and ownership model.

The company offers a wide range of products that allow it to serve diverse tastes and customer groups.

Patel Retail has been involved in the manufacturing, trading, and exporting of wheat flour, spices, peanuts, and fruit pulps/concentrates, consistently delivering quality products to its customers.

With the opening of 3 new stores in FY24, 9 new stores in FY2025, and 1 new store in the first two months of FY2026, the company has shown a strong track record of growth and profitability.

Weaknesses:

Its retail stores are mostly situated in Maharashtra, in the Thane and Raigad districts. In FY25, 24, and 23, most of the revenue was generated from retail sales from these regions, meaning any issues that occur in those regions can negatively impact the business and the company’s finances.

Patel Retail consists of a total of 43 stores, with 8 operating for over 5 years and 15 for over 10 years. The older stores may seem to have a price drop in sales, if the drop in sales continues could hurt their business.

The business mostly runs on raw materials like wheat, spices, and peanuts. However, the company did not sign the long-term contract with them, meaning that if any price rise, shortage, or seasonal variation occurs can badly impact the business, financial operations, and cash flow.

Patel Retail IPO Details

IPO Size	₹242.76 crores
Offer-for-sale	10,02,000 equity shares
Fresh issue	₹215.91
Price band	₹237 to ₹255
Subscription	Opens on August 19, 2025, and closes on August 21, 2025
Purpose of IPO	Offer-for-Sale and Fresh Issue

Patel Retail IPO Open and closing date?

The opening date of a Patel Retail IPO is August 19, 2025, and the closing date of the IPO is August 21, 2025.

What is the size of the Patel Retail IPO?

The company planned to raise funds of around ₹242.76 crores via IPO. This IPO comprises only an Offer-for-sale (OFS) component of up to 10,02,000 equity shares with a face value of ₹10 each.

What are the subscription details for the Patel Retail IPO?

An Patel Retail IPO price range is set at ₹237 to ₹255 per share. In this IPO, a total of 58 shares were available in 1 lot size for the minimum Retail category, and for the maximum retail category, 754 shares in 13 lot sizes were available, and for the S-HNI Minimum category, 812 shares were available in 14 lot sizes. While for the B-HNI Minimum category, 3,944 shares were available in 68 lot sizes.

To invest in this IPO, each investor category has specific investment amounts:

Retail Investors: Minimum investment of ₹14,790 and maximum investment of ₹1,92,270.
Small HNI (S-HNI): Minimum investment of ₹2,07,060.
Big HNI (S-HNI): A minimum investment of ₹10,05,720 is required.

What is the listing date of the Patel Retail IPO?

Patel Retail is a Mainboard IPO whose shares will be listed on August 26, 2025, on the BSE (Bombay Stock Exchange) & NSE (National Stock Exchange).

What are the objectives of the Patel Retail IPO Issue?

The proceeds raised from the fresh issue will be utilized for the repayment/prepayment of certain borrowings taken by the company. Some funds will be used for the working capital requirements of the Company. Lastly, the remaining funds will be used for the company’s general corporate purposes.

About Patel Retail

Incorporated in 2008, Patel Retail Limited is one of the well-known retail supermarket chains serving mainly tier-III cities and nearby suburbs, offering food, FMCG, general merchandise, and apparel. Initially, the company opened its single store under the brand name “Patel’s R Mart” in Maharashtra, and within no time, they expanded to around 43 stores. The company emphasizes quality as essential for a positive customer experience and long-term brand loyalty. Between 2021 and 2023, total revenue grew at an average annual rate of 11%, rising from ₹82,775.34 lakh to ₹1,01,980.36 lakh. As of May 31, 2025, the company operated 43 stores across the suburban areas of Thane and Raigad districts in Maharashtra. The company’s portfolio comprises pulses, ready mixes, Indian Chaska” (spices, ghee, and papad), “Blue Nation” (men’s wear), and “Patel Essentials” (home improvement items).

Patel Retail IPO Financials

The company reported revenue of ₹825.99 crores in 2025 against ₹817.71 crores in 2024. The company reported a profit of ₹25.28 crores in 2025 against a profit of ₹22.53 crores in 2024.

Patel Retail IPO Promoters

The promoters of the company are Dhanji Raghavji Patel, Bechar Raghavji Patel, Hiren Bechar Patel, and Rahul Dhanji Patel.

Who are the Patel Retail IPO lead managers and registrar?

FedEx Securities Pvt Ltd is the lead manager of Patel Retail, while Bigshare Services Pvt Ltd is the registrar to the company.

Should you Apply or not for Patel Retail IPO?

Patel Retail Limited is one of the growing companies involved as a retail supermarket chain operating in tier-III cities strong presence in Maharashtra, mainly in Thane and Raigad districts. The company started its business under the brand name “Patel’s R Mart” and offers around 38 product categories with over 10,000 product SKUs in its store, and, with time, expanded its business by managing 43 stores as of May 31, 2025.

If we talk about the company’s financials, over the years, the company has done amazing with showing steady revenue growth. However, in recent years, we have seen some decline in revenue and store sales, which investors must keep in mind before investing in it. Sole reliance on a limited geographical area and price fluctuation in the raw material are some of the risks that one should keep in mind.

At the end of the day, it is your responsibility to first check if this IPO is good or bad, or whether you should apply or not, by checking the company’s financial growth and potential to avoid any loss of money. For more information and queries, please connect with our IPOWatch team. We are always ready to help and solve your queries.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.